Time to untreatable progression is an appropriate surrogate endpoint for overall survival in patients with hepatocellular carcinoma after transarterial chemoembolization
Conclusion: Untreatable progression is more representative of clinical progression in patients with HCC who underwent TACE. In the current study, TTUP is a more appropriate surrogate endpoint for OS than TTP. Future studies should explore whether untreatable progression is a valuable endpoint event in clinical trials or an indicator of the need for second-line therapy.
Source: Journal of Cancer Research and Therapeutics - Category: Cancer & Oncology Authors: Hongyu Wang Bin Li Yu Wang Jiang Zhang Yanqin Wu Wenzhe Fan Jiaping Li Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Clinical Trials | Hepatocellular Carcinoma | Liver | Liver Cancer | Study | Urology & Nephrology